Connect with us

Headlines of The Day

Jupiter Life Line Hospitals Q4 review: Greenfield expansion to drive growth

Jupiter Life Line Hospitals Ltd.’s Q4 consolidated Ebitda grew by 21% YoY (1% QoQ) to Rs 623 million; in line with our estimates aided by higher average revenue per occupied bed.

Jupiter Life Line Hospitals’ operational efficiency has been strong in competitive markets of Mumbai Metropolitan Region.

The company reported revenue/Ebitda compound annual growth rate of 24%/35% over FY21- 24. Given expansion plans, scale up in occupancy and improving margins, business is expected to aid growth momentum over the medium term in our view.

We believe strategic greenfield expansions in densely populated micro markets of western regions augur well to drive sustainable growth. Overall we see 25%/25% Ebitda/PAT CAGR over FY24- 26E with healthy return ratios of ~20%.

Maintain ‘Buy’ rating with a target price of Rs 1,360/share valuing at 23 times enterprise value/Ebitda based on FY26E Ebitda.

For full report click. Prabhudas Lilladher

Copyright © 2024 Medical Buyer

error: Content is protected !!